Amundi
NTLA icon

Amundi’s Intellia Therapeutics NTLA Stock Holding History

Amundi’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,161
Closed -$91.3K – 2078
2025
Q4 		$91.3K Buy
+10,161
New +$140K ﹤0.01% 1816
2025
Q2 		– Sell
-5,065
Closed -$34.9K – 2007
2025
Q1 		$34.9K Sell
5,065
-43,730
-90% -$442K ﹤0.01% 1835
2024
Q4 		$587K Sell
48,795
-11,987
-20% -$187K ﹤0.01% 1534
2024
Q3 		$1.09M Buy
60,782
+20,508
+51% +$473K ﹤0.01% 1275
2024
Q2 		$924K Sell
40,274
-17,054
-30% -$406K ﹤0.01% 1222
2024
Q1 		$1.22M Buy
57,328
+820
+1% +$22.8K ﹤0.01% 1251
2023
Q4 		$1.66M Sell
56,508
-9,466
-14% -$272K ﹤0.01% 1242
2023
Q3 		$1.97M Buy
65,974
+20,897
+46% +$811K ﹤0.01% 1180
2023
Q2 		$1.84M Buy
45,077
+27,294
+153% +$1.11M ﹤0.01% 1175
2023
Q1 		$636K Buy
17,783
+847
+5% +$33.2K ﹤0.01% 1329
2022
Q4 		$635K Sell
16,936
-6,490
-28% -$309K ﹤0.01% 1363
2022
Q3 		$1.43M Buy
23,426
+12,819
+121% +$795K ﹤0.01% 1193
2022
Q2 		$677K Buy
10,607
+4,720
+80% +$240K ﹤0.01% 1230
2022
Q1 		$388K Buy
5,887
+3,750
+175% +$318K ﹤0.01% 1322
2021
Q4 		$191K Buy
2,137
+291
+16% +$36.5K ﹤0.01% 1485
2021
Q3 		$248K Buy
+1,846
New +$279K ﹤0.01% 1415

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Amundi's NTLA Position: Q1 2026 in Review

Amundi sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 10,161 shares — an estimated $91.3K sold.

Amundi first reported a position in NTLA in Q3 2021 and held it in 16 quarters. The position peaked at $1.97M in Q3 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Amundi reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amundi sold 10,161 Intellia Therapeutics shares in Q1 2026, an estimated $91.3K.
  • Amundi first reported a position in Intellia Therapeutics in Q3 2021 and held it in 16 quarters.
  • Amundi's Intellia Therapeutics position peaked at $1.97M in Q3 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.